Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Samsung Biologics (207940 KS)
Watchlist
331
Analysis
Health Care
•
South Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Celltrion Inc
•
22 Apr 2017 02:17
The Disconnect Is Growing
Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...
Kemp Dolliver, CFA
608 Views
Share
bearish
•
Samsung Biologics
•
11 Mar 2017 06:29
Reconsider the Samsung Bioepis Valuation
As noted in our Insight Pass on the Deal, Put on the Watchlist one of the underpinnings of the valuation of Samsung Biologics Co., Ltd (207940 KS)...
Kemp Dolliver, CFA
769 Views
Share
bullish
•
Wuxi Biologics
•
15 Feb 2017 01:41
An Early Look at WuXi Biologics
WuXi Biologics, a CRO/contract manufacturer focused on biologics, has filed an Application Proof with the HKEX for a new listing. The document...
Kemp Dolliver, CFA
846 Views
Share
bullish
•
Samsung Biologics
•
05 Feb 2017 16:08
Revisiting Samsung BioLogics at This Interesting Time
I don't really intend to make any investment recommendation on BioLogics at this point. I have to admit that I'm still feeling the current price is...
Sanghyun Park
Follow
248 Views
Share
bearish
•
Celltrion Inc
•
20 Jan 2017 20:59
Recent Developments Not Encouraging
This Insight provides an update on developments in the US market related to biosimilars, and are of great significance to Celltrion Inc (068270...
Kemp Dolliver, CFA
159 Views
Share
First
Previous
57
58
59
60
61
62
63
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5
x